Legato Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Legato Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-40,393	Closed	-$954K	–	631
2023 Q4	$954K	Buy	40,393 +19,867	+97%	+$354K	0.12%	279
2023 Q3	$306K	Buy	+20,526	New	+$272K	0.04%	473

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Legato Capital Management's CBAY Position: Q1 2024 in Review

Legato Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 40,393 shares — an estimated $954K sold.

Legato Capital Management first reported a position in CBAY in Q3 2023 and held it in 2 quarters. The position peaked at $954K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Legato Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Legato Capital Management sold 40,393 Cymabay Therapeutics shares in Q1 2024, an estimated $954K.
Legato Capital Management first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 2 quarters.
Legato Capital Management's Cymabay Therapeutics position peaked at $954K in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Legato Capital Management's 13F filing for Q1 2024, filed 15 Apr 2024.